GLP-1 + GH Secretagogue Stack: Weight Loss and Body Composition

GLP-1 + GH Secretagogue Stack: Weight Loss and Body Composition

Key Takeaways:

• GLP-1 agonists (semaglutide, tirzepatide) drive significant weight loss but are associated with muscle mass loss alongside fat reduction. Studies show 25-40% of weight lost on GLP-1s can come from lean tissue.
• GH secretagogues (ipamorelin, CJC-1295, MK-677) stimulate growth hormone, which supports lean mass preservation, lipolysis, and recovery. Adding one to a GLP-1 protocol addresses a documented limitation.
• These two compound classes work through entirely different mechanisms, making the stack rationally sound from a mechanistic standpoint.
• The combination has not been studied in randomized controlled trials. Protocols come from the peptide therapy community and clinical experience of providers.
• Blood work before starting is mandatory. Both compound classes affect metabolic markers that require monitoring.

Important: This is not medical advice. The information below covers published research on individual compounds and community-reported stacking protocols. Consult a qualified healthcare provider before starting any peptide protocol. GLP-1 agonists (semaglutide, tirzepatide) are FDA-approved medications with established prescribing guidelines. GH secretagogues are research compounds not FDA-approved for human use. See our full medical disclaimer.

---

The core problem this stack is designed to solve

GLP-1 agonists are the most effective weight loss intervention most people will ever encounter. Semaglutide trials show 15-17% average body weight reduction. Tirzepatide trials show 20-22% in some populations. These are genuinely remarkable numbers.

The problem is what gets lost along with the fat.

In clinical trials, a significant portion of weight lost on GLP-1 agonists comes from lean mass, not fat alone. A 2023 analysis found that roughly 25-40% of total weight lost on semaglutide came from lean tissue rather than fat mass, depending on the study population and whether resistance training was part of the protocol. This is not a small concern. Muscle is metabolically active tissue. Losing it during a weight loss phase makes weight maintenance harder, reduces strength and function, and can leave people at a lower but still metabolically compromised body composition.

This is the gap the GLP-1 plus GH secretagogue stack is designed to address.

Growth hormone plays a well-documented role in lean mass preservation and lipolysis (the mobilization of fat for fuel). A GH secretagogue running alongside a GLP-1 agonist works in a complementary direction: the GLP-1 reduces appetite and drives a caloric deficit; the GH secretagogue signals the body to preserve muscle and preferentially burn fat. The mechanisms do not interfere with each other. They target different systems.

Our research on GLP-1 and muscle loss covers the lean mass concern in depth if you want the full data picture before reading about the stack.

How GLP-1 agonists work

GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It signals the pancreas to release insulin, suppresses glucagon, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite and increase satiety.

Pharmaceutical GLP-1 agonists mimic this hormone with dramatically extended half-lives:

• Semaglutide (Wegovy/Ozempic): Weekly injection, GLP-1 receptor agonist only
• Tirzepatide (Zepbound/Mounjaro): Weekly injection, dual GLP-1 and GIP receptor agonist. The dual mechanism is why tirzepatide shows larger weight loss in clinical trials.

Both are FDA-approved for obesity treatment. Both require a prescription and should be obtained through a licensed healthcare provider or compounding pharmacy operating within regulatory guidelines.

The weight loss mechanism is primarily caloric deficit driven by appetite suppression, improved satiety, and reduced food cravings. Metabolic improvements (insulin sensitivity, fasting glucose, triglycerides) are additive benefits beyond weight loss.

How GH secretagogues work

GH secretagogues stimulate the pituitary gland to release growth hormone. They do not supply GH directly. Instead, they trigger your own pituitary to produce more of it, maintaining the natural pulsatile pattern of GH secretion.

There are two pathways stimulated by different compounds:

GHRP pathway (ghrelin receptor agonists): Ipamorelin, GHRP-2, GHRP-6. These mimic ghrelin and directly stimulate the pituitary. Ipamorelin is preferred for this stack because it has a selective action on GH release with minimal effect on cortisol or prolactin, which matters when you are already managing a significant dietary intervention.

GHRH pathway (growth hormone-releasing hormone analogs): CJC-1295 (without DAC), sermorelin. These stimulate GH production from the other arm of the hypothalamic-pituitary axis. Combining a GHRP with a GHRH analog produces a more complete, more physiological GH pulse than either alone.

MK-677 (Ibutamoren): An oral ghrelin mimetic. Not a peptide in the strict sense, but categorized with GH secretagogues due to its mechanism. Human studies show it reliably increases IGF-1 and improves sleep architecture, specifically slow-wave sleep (PMID: 10817111, 19395468). The tradeoff is less precise dosing control and more pronounced appetite stimulation, which can work against the appetite-suppressing goals of a GLP-1 protocol.

For this stack, ipamorelin paired with CJC-1295 (no DAC) is the most commonly cited injectable option. MK-677 is used by some, but its appetite-stimulating effect creates a direct tension with the GLP-1's appetite suppression goals and requires careful monitoring. You can find more detail on the GH secretagogue options on our GH secretagogues page.

Why these mechanisms complement each other

The mechanism-level case for combining GLP-1 agonists and GH secretagogues:

GLP-1 effects:

• Reduces appetite and caloric intake
• Improves insulin secretion and sensitivity
• Slows gastric emptying
• Drives caloric deficit that produces weight loss

GH secretagogue effects:

• Stimulates lipolysis (fat mobilization for fuel)
• Supports protein synthesis and lean mass preservation
• Improves sleep quality (much of muscle repair and GH secretion happens during slow-wave sleep)
• Increases IGF-1, which has downstream anabolic and recovery-supporting effects

The GLP-1 creates the deficit. The GH secretagogue signals the body to fill that deficit preferentially from fat while preserving muscle. These are not redundant mechanisms. They address different parts of the body composition equation.

The one area of potential concern is insulin sensitivity. Both GH (via downstream effects) and GLP-1 affect glucose metabolism from different angles. GH can increase insulin resistance at high levels; GLP-1 improves insulin sensitivity. The net effect of their combination requires monitoring rather than assumption.

Community protocols

The following protocols are drawn from the peptide therapy community and reflect commonly reported approaches. They are not clinical prescriptions.

Protocol A: Injectable (ipamorelin + CJC-1295 with GLP-1)

GLP-1 agonist:

• Semaglutide or tirzepatide at prescribed dose, titrated per standard clinical protocol
• Weekly subcutaneous injection, typically in the abdomen

GH secretagogue:

• Ipamorelin: 200-300 mcg subcutaneously at bedtime
• CJC-1295 (no DAC): 200-300 mcg subcutaneously at bedtime (same injection)
• 5 days on / 2 days off, or daily depending on individual protocol
• Cycle: 12 weeks on, 4 weeks off

Rationale for bedtime dosing: Growth hormone has a natural nocturnal peak during slow-wave sleep. Dosing GH secretagogues at bedtime amplifies this natural pulse and maximizes the sleep-quality benefit.

Protocol B: Oral option (MK-677 with GLP-1)

GLP-1 agonist: Same as above

MK-677:

• 12.5-25 mg orally, taken at bedtime
• Daily dosing (MK-677 has a long half-life, approximately 24 hours)
• Cycle: 16-24 weeks continuous, then 4-8 weeks off

Caution: MK-677's appetite-stimulating effect can partially counteract GLP-1's appetite suppression. Some individuals find the combination manageable; others find that MK-677's hunger drive undermines the GLP-1 benefit. Starting at 12.5 mg before increasing is advisable.

Resistance training: the third variable

No stack maximizes muscle preservation without resistance training. This is not a minor point.

GH secretagogues support an anabolic environment. They do not build muscle on their own. Resistance training is the stimulus that tells the body where to direct the anabolic signals. Combining a GLP-1 with a GH secretagogue but skipping resistance training means the GH benefits are not fully expressed.

A minimum of 2-3 resistance training sessions per week is typically recommended alongside any GLP-1 protocol aimed at body composition rather than just scale weight. Progressive overload (gradually increasing weights or volume) is important for maintaining the stimulus as strength improves.

Protein intake also matters. High protein intake during a caloric deficit supports lean mass preservation regardless of compound use. Most protocols in the peptide therapy community recommend 0.7-1 gram of protein per pound of bodyweight during active GLP-1 protocols.

Required monitoring

This combination affects multiple metabolic markers. Monitoring is not optional.

Before starting:

• Fasting glucose and insulin
• HbA1c
• IGF-1
• Complete blood count and comprehensive metabolic panel
• Thyroid panel (GLP-1 agonists carry an FDA black box warning for thyroid C-cell tumors in animal studies)

During the protocol (every 4-8 weeks):

• Fasting glucose (GH can affect insulin sensitivity)
• IGF-1 (to confirm GH secretagogue is having its intended effect and to ensure levels are not becoming supraphysiologic)
• Body composition assessment (DEXA scan is preferred over scale weight alone)

Red flags requiring immediate stop:

• Fasting glucose rising into pre-diabetic or diabetic range
• IGF-1 climbing above the high end of normal for your age group
• Persistent severe nausea beyond the typical GLP-1 titration side effect window
• Unexplained swelling or edema that does not resolve

Who this stack is and is not for

Good candidates:

• People currently on a GLP-1 agonist who are losing significant lean mass and want to preserve muscle
• People with obesity who have prioritized fat loss but want body composition optimization, not just scale weight reduction
• People with documented GH decline (confirmed by low IGF-1 on blood work) who are also managing weight

Not appropriate for:

• People with active or recent cancer history. GH and IGF-1 are mitogenic. This is a hard contraindication that requires oncologist clearance.
• People with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. These are contraindications for GLP-1 agonists specifically.
• People with poorly controlled diabetes who are not under close medical supervision. Both compounds affect glucose metabolism.
• People with untreated pituitary disorders.

---

Frequently Asked Questions

Will adding a GH secretagogue reduce GLP-1 side effects? No. GH secretagogues do not address GLP-1 side effects (nausea, GI upset, slow gastric emptying). Those are managed through proper titration of the GLP-1 dose. Do not add a GH secretagogue as a nausea mitigation strategy. Add it for lean mass preservation.

How much muscle can you actually preserve by adding a GH secretagogue? No controlled trial has studied this combination specifically, so there is no precise number. The individual evidence for GH secretagogues supporting lean mass is documented in trials like the MK-677 IGF-1 studies (PMID: 19395468). The expectation from the mechanistic rationale and community experience is meaningful but not quantified in controlled human data.

Can you start the GH secretagogue at the same time as the GLP-1? Most community protocols suggest starting the GLP-1 first and allowing several weeks for side effects to settle before adding the GH secretagogue. This avoids confounding side effect attribution if something goes wrong.

Does tirzepatide work better than semaglutide in this stack? Tirzepatide's dual GLP-1 and GIP mechanism produces larger average weight loss in trials. Whether that translates to better outcomes in the specific context of this combined stack is unknown. The choice between semaglutide and tirzepatide should be made based on clinical factors, not the assumption of stack compatibility.

How long before you see body composition changes? GLP-1 effects on appetite are typically felt within the first week. Meaningful scale weight changes occur within 4-8 weeks depending on dose. Body composition changes (muscle preservation assessment vs. fat loss) are best evaluated at 12 weeks via DEXA scan.

---

Sources

1. Copinschi G, et al. "Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man." PMID: 10817111
2. Murphy MG, et al. "MK-0677, a potent, orally active growth hormone secretagogue, reverses diet-induced catabolism." PMID: 19395468
3. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021. (SURMOUNT-1 and STEP trials for semaglutide and tirzepatide lean mass data referenced from published analyses.)
4. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. 2022.

---

The information in this article is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. See our full disclaimer.